Next-generation peptide vaccines for advanced cancer

Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer

(2012) Yasuhiro Terazaki et al.   CANCER SCIENCE

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

(2012) Norihiko Takahashi et al.   CANCER SCIENCE

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

(2011) Jianda Yuan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

(2011) Osama E. Rahma et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer

(2011) M. A. Morse et al.   CLINICAL CANCER RESEARCH

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

(2011) Kazuhiro Kakimi et al.   INTERNATIONAL JOURNAL OF CANCER

Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer

(2011) Ninke Leffers et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine

(2011) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

(2011) Masanori Noguchi et al.   PROSTATE

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

(2010) P. G. Maslak et al.   BLOOD

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

(2010) Lee M. Krug et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

(2010) Jürgen Kuball et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

(2010) Masanori Noguchi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

(2010) S. A. Perez et al.   CLINICAL CANCER RESEARCH

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

(2010) A. A. Sarnaik et al.   CLINICAL CANCER RESEARCH

Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme

(2010) Mizuhiko Terasaki et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer

(2010) Masanori Noguchi et al.   PROSTATE

Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer

(2009) F. M. Speetjens et al.   CLINICAL CANCER RESEARCH

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2009) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer

(2009) Susan Feyerabend et al.   PROSTATE

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH

Recent Advances in Cancer Vaccines: An Overview

(2008) K. Itoh et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

(2008) Minal Barve et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

(2008) Kimberly A. Chianese-Bullock et al.   JOURNAL OF IMMUNOTHERAPY